- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00823953
Glycemic Response to Momordica Charantia in Type 2 Diabetes
The Effect of Momordica Charantia on Glycemic Control and Insulin Resistance in Type 2 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Punjab
-
Lahore, Punjab, Pakistan, 54000
- Services Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult Type 2 diabetics with mild degree of hyperglycemia (FBG >126<200 mg/dl)
- Absence of serious co-morbid conditions
- Patients agreeing to participate in this trial
Exclusion Criteria:
- Type 1 diabetics
- Pregnancy
- Paediatric age group
- Patients known to be allergic to Momordica charantia
- Serious cardio-respiratory illness, previous myocardial infarction, angina pectoris, heart failure, uncontrolled hypertension ≥ stage 2, COPD, asthma, active pulmonary tuberculosis
- Significant hepatic impairment: ALT >60, Bilirubin >2 mg/dl
- Significant renal impairment: S/creatinine >1.5 mg/dl, albuminuria > 1+
- Patients with conditions likely to interfere with the absorption of the trial therapy: malabsorption, chronic diarrhoea, intestinal resection, blind loop syndrome
- Patients withholding consent
- Patients, both male and female, desiring pregnancy during the trial phase.
- Secondary causes of diabetes
- Patients using drugs influencing glucose metabolism: steroids, hormonal contraception, menopausal HRT , diazoxide, phenytoin, colchicine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
placebo powder (wheat flour) The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
|
The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
|
Active Comparator: Momordica charantia
Thirty patients will be assigned to each arm in a double blind manner. The active arm will be administered capsules containing a total of 500 mg of Momordica charantia freeze dried powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3. The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3. |
escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia.
Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia.
Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
serum fructosamine at end of trial phase in each of the groups
Time Frame: three weeks
|
three weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Development of major adverse effects (e.g. intractable vomiting, jaundice, allergic reactions or other effects requiring cessation of therapy and breaking of study code)
Time Frame: three weeks
|
three weeks
|
GLP-1[7-36] in each group at the end of trial phase
Time Frame: three weeks
|
three weeks
|
FBG at end of trial phase in each of the groups
Time Frame: three weeks
|
three weeks
|
HOMA-IR in each of the two groups at end of trial phase
Time Frame: three weeks
|
three weeks
|
Insulin resistance by the hyperinsulinemic, euglycemic clamp in a subset at the end of trial phase
Time Frame: 3 weeks
|
3 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Khadija I Khawaja, MBBS,FCPS, Services Hospital, Lahore
Publications and helpful links
General Publications
- Ahmed I, Adeghate E, Sharma AK, Pallot DJ, Singh J. Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes Res Clin Pract. 1998 Jun;40(3):145-51. doi: 10.1016/s0168-8227(98)00022-9.
- Ahmed I, Lakhani MS, Gillett M, John A, Raza H. Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract. 2001 Mar;51(3):155-61. doi: 10.1016/s0168-8227(00)00224-2.
- Dans AM, Villarruz MV, Jimeno CA, Javelosa MA, Chua J, Bautista R, Velez GG. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol. 2007 Jun;60(6):554-9. doi: 10.1016/j.jclinepi.2006.07.009. Epub 2006 Nov 13.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DMC0107
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on starch powder
-
Probi ABTerminatedGynecologic Cancer | Gastrointestinal ToxicitySweden
-
University of the PunjabUniversity of Veterinary and Animal Sciences, Lahore - PakistanNot yet recruitingChild MalnutritionPakistan
-
The Korean Society of GinsengCompleted
-
Changhua Christian HospitalRecruiting
-
The Herb, IncProRelix Services LLPCompleted
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health Clinical Center (CC)RecruitingMilk and/or Peanut AllergyUnited States
-
National Taiwan Sport UniversityCompleted
-
University of Illinois at Urbana-ChampaignCompletedQuality of Life | Obesity | Metabolic Syndrome | Physical Function | Bone and Body CompositionUnited States
-
The Korean Society of GinsengCompleted
-
University of ManitobaRecruitingChronic Kidney DiseasesCanada